Novartis Falls 12.93% as Del-Desiran Misses in Phase 3

Novartis shares fell 12.93% to 139.30 on 8 September 2026 after the phase 3 Harbor trial of del-desiran, the lead asset from its $12 billion takeover of Avidity Biosciences, missed its primary endpoint.

Novartis AG (NVS) was down 12.93% at 139.30 in intraday trade as of 13:53 GMT on 8 September 2026, after the phase 3 Harbor trial of del-desiran failed to hit its primary endpoint. The drug was the centerpiece of the Swiss group's $12 billion acquisition of Avidity Biosciences — the reason the deal was priced where it was priced — and the readout removes the single clearest source of value investors had underwritten.

The scale of the move tells you how concentrated the bet had become. Novartis shares closed the prior session at 159.99; the intraday print of 139.30 is 20.69 points lower, a decline entirely of the company's own making on a day when the broad market barely moved. The S&P 500 tracker (SPY) was off 0.41% at $767.07, the Nasdaq 100 tracker (QQQ) down 0.29% at $716.85, and the Dow tracker (DIA) down 0.89% at $529.32. A double-digit percentage drop in a mega-cap pharmaceutical name against that backdrop is a single-stock repricing, not a sector rotation.

What a missed primary endpoint costs a $12 billion deal

A primary endpoint is the one pre-specified measure a trial is designed and powered to answer. Regulators treat it as the question the study was built to settle; missing it means the trial did not demonstrate what the sponsor set out to demonstrate, whatever the secondary measures show. It is the difference between a filing package and a research problem.

That distinction matters more than usual here because del-desiran was not one asset among many in the Avidity transaction — it was described as the centerpiece. When a buyer pays $12 billion and the acquisition thesis rests on a lead programme, the phase 3 readout is effectively a referendum on the purchase price. Illustratively, if the market had assigned even half of the $12 billion consideration to del-desiran, that would be $6 billion of the deal's rationale now sitting on far shakier ground — a framing exercise rather than a reported valuation, but one that explains why the shares moved as sharply as they did.

Acquired platforms rarely fail cleanly. Avidity's appeal to Novartis was not only a single molecule but the technology behind it, and a phase 3 miss on the lead candidate raises the harder question of whether the problem is the target, the dose, the trial design, or the delivery approach itself. Those are four very different answers with four very different price tags, and the market does not have to wait for the distinction to be resolved before it marks the equity down.

One win, two failures, and a pipeline narrative under strain

The Harbor miss does not arrive in isolation. As Fierce Biotech reported, the failure leaves Novartis with one success and two failures from a rapid-fire sequence of key clinical readouts. Compressed readout calendars cut both ways: a run of wins compounds a growth story quickly, and a run of misses removes several supports at once, with no time in between for management to reset expectations.

Large pharmaceutical companies are valued substantially on the credibility of what comes next. Marketed products generate the cash, but the multiple attached to that cash reflects the market's belief that the pipeline will replace revenue as patents expire. Two failures out of three high-profile readouts attacks that belief directly, and it does so at the same moment as a headline acquisition is called into question. The equity is not just discounting one lost drug; it is discounting a slightly lower probability of success attached to everything still in development.

Where the pressure lands next

Several things now matter more than the headline itself.

• The full Harbor dataset. How far the trial missed by, and what the secondary endpoints and subgroups show, will determine whether del-desiran is salvageable through a redesigned study or effectively finished.
• Whether the read-through hits the platform. If the failure is judged mechanistic rather than trial-specific, other programmes built on the same approach come under the same doubt — and that is where the remaining Avidity value sits.
• Accounting consequences. A $12 billion purchase price supported principally by one asset invites scrutiny of carrying values. Impairment questions typically surface at the next reporting period rather than on the day of the news.
• Capital allocation. A company that has just written a $12 billion cheque and lost its lead readout faces a sharper set of choices between further business development, buybacks and internal spending.

How the tape is treating the news

The intraday range tells its own story. Novartis traded between 139.25 and 140.46 during the session — a narrow band near the low, with no meaningful attempt to recover ground from the opening gap. Stocks that gap down on data and then chop sideways at the bottom of the range are usually being repriced by holders reducing exposure rather than traded by buyers hunting a dislocation. Compare that with the benchmarks, which were all within roughly a point or two of their previous closes.

For pharmaceutical investors, the broader lesson is about concentration risk in dealmaking. Paying a premium for a single late-stage asset transfers binary clinical risk onto the acquirer's balance sheet at exactly the moment the seller's shareholders have been paid in full. Novartis retains the marketed portfolio, the cash generation and the rest of the pipeline; what it has lost is the asset that justified a $12 billion outlay and the benefit of the doubt on the readouts still to come.

Key facts

• NVS share price: 139.30, -12.93% as of 13:53 GMT, 8 Sep 2026 (prev close 159.99)
• Trial: Phase 3 Harbor study of del-desiran missed its primary endpoint
• Deal at stake: $12 billion acquisition of Avidity Biosciences; del-desiran was the centerpiece
• Readout record: One win, two failures across a rapid-fire run of key readouts

Frequently asked questions

What happened to Novartis shares?

Novartis (NVS) traded at 139.30 as of 13:53 GMT on 8 September 2026, down 12.93% from the previous close of 159.99. The intraday range was 139.25 to 140.46, meaning the stock stayed near its lows for the session rather than recovering from the opening decline on the trial news.

What is del-desiran and why does it matter?

Del-desiran is the drug candidate Novartis acquired through its $12 billion takeover of Avidity Biosciences, and it was described as the centerpiece of that transaction. Because so much of the deal's rationale rested on this single asset, the phase 3 Harbor trial's failure to meet its primary endpoint undercuts the logic of the purchase price.

What does missing a primary endpoint mean?

The primary endpoint is the single pre-specified measure a trial is designed and statistically powered to answer. Regulators treat it as the decisive question. Missing it means the study did not show what the sponsor set out to show, regardless of secondary results, and it usually blocks a straightforward regulatory filing based on that trial.

How did the wider market perform that day?

Benchmarks were close to flat. The S&P 500 tracker SPY was at $767.07, down 0.41%; the Nasdaq 100 tracker QQQ was at $716.85, down 0.29%; and the Dow tracker DIA was at $529.32, down 0.89%. Novartis's 12.93% decline was therefore company-specific rather than a market-wide move.

How many recent Novartis readouts have failed?

Novartis has recorded one win and two failures across a rapid-fire run of key clinical readouts, with the Harbor miss the latest. A compressed readout calendar means several pipeline supports can be tested in quick succession, leaving little time for management to reset expectations between results.

What should investors watch next?

The full Harbor dataset, including how far the trial missed and what secondary endpoints show, will indicate whether del-desiran can be revived. Beyond that, whether the failure reads across to other programmes using the same technology, any impairment of the $12 billion purchase price, and how Novartis reallocates capital.

Sources

• Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test — Fierce Biotech

Photo: Jess Loiterton · Pexels Licence — source